FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person Scott Kathleen D.					<u>Der</u>	2. Issuer Name and Ticker or Trading Symbol Dermata Therapeutics, Inc. [DRMA]									5. Relationship of Reportir (Check all applicable) X Director			g Person(s) to Issuer 10% Owne	
(Last)	(First)	,	ddle)			3. Date of Earliest Transaction (Month/Day/Year) 10/06/2022									Officer (g below)	fficer (give title elow)		Other (s below)	specify
3525 DEL MAR HEIGHTS RD. #322					4. If Amendment, Date of Original Filed (Month/Day/Year)								- 1	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Street) SAN DIEGO	CA	92	130												Form file	d by More	than O	ne Reportin	g Person
(City)	(State)	(Zi _l	o)																
		Та	ble I - Nor	n-Der	ivativ	e Se	ecuritie	s Acq	uired, l	Disp	osed of,	or Be	enefi	cially Ow	ned				
Date				:h/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a				Following	ities icially Owned ving Reported		nership Direct (D) irect (I) 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount		A) or D)	Price	Transaction(s) (Instr. 3 and 4)				(IIIStr. 4)	
Common Stock 10/06				6/2022	5/2022 ⁽¹⁾		Α		11,359		A	\$ <mark>0</mark>	27,145		D				
Common Stock														2,439		I		By Scott 2008 Trust Dated 3/28/08	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ise (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate,	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Dat (Month/Day/Ye		e Securities Under		derlying curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	or Nu		Amount or Number of Shares	(Instr. 4)		on(s)		

Explanation of Responses:

1. On October 6, 2022, the Reporting Person was granted 11,359 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.

/s/ Gerald T. Proehl, Attorney-in-

Date

Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).